Drug Type Small molecule drug |
Synonyms APL 5125, APL5125 |
Target- |
Mechanism kinase inhibitor |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Apollo Therapeutics LLPStartup |
Active Organization Apollo Therapeutics LLPStartup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Appendiceal Neoplasms | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Bile Duct Neoplasms | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Colorectal Cancer | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Ovarian Cancer | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Pancreatic adenocarcinoma | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Prostatic Cancer | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
stomach adenocarcinoma | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
Triple Negative Breast Cancer | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |
uterus adenocarcinoma | Phase 2 | US | Apollo Therapeutics LLPStartup | 18 Jun 2024 |